Cardiovascular Drugs Market Size Worth $63.96 Billion by 2026; Increasing Prevalence of Cardiovascular Diseases will Accelerate Growth

The global cardiovascular drugs market size is expected to reach USD 63.96 billion by 2026. The increasing awareness about the impact of cardiovascular diseases to human health is one of the prime reasons enabling the growth of the market, says Fortune Business Insights in a report, titled “Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), By Disease Indication (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026” The cardiovascular drugs market was USD 47.29 billion in 2018 and is expected to exhibit a CAGR of 3.8% from 2019 to 2026.

Escalating Demand for Novel Drugs will Spur Growth Opportunities

The increasing focus of key players towards the development of novel drugs and therapeutics will boost the market growth in the foreseeable future. One of the vital factors spurring the demand for novel therapies is the growing awareness regarding cardiovascular health and advanced treatment. In addition to this, the increasing product launches by key players will add up to the surge in the market revenue.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/cardiovascular-therapeutics-market-100379

Leading Segments in the Market

• Drug Type: Under this segment, the market is classified into antihypertensive, antihyperlipidemic, anticoagulants, antiplatelet drugs, and others. The anticoagulants segment is expected to dominate the market during the forecast period owing to their critical life-preserving functions. The presence of Eliquis will further aid the growth of the anticoagulants segment. Antihypertensive, antihyperlipidemic, and antiplatelet drugs are expected to contribute healthy growth to the market due to its wide consumption globally.


•  Disease Indication: Under the segment, the market is categorized into hypertension, hyperlipidemia, coronary artery disease, arrhythmia, and others. The hypertension segment will witness high growth in the forthcoming year owing to its prevailing cases of cardiovascular disease. An increasing number of patients around the world will contribute to segment growth. Hypertension is one of the key reasons for heart attack, a life-threatening cardiovascular condition. Furthermore, the increasing incidence of hyperlipidemia will boost the growth of the market. For instance, individuals with hyperlipidemia are at twice the risk of developing cardiovascular diseases. Cardiovascular drugs market trends include the rise in the treatment and management of diverse heart diseases such as arrhythmia. This trend will speed up the growth process.


• Distribution Channel: Under the segment, the market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The Hospital pharmacies segment will account for maximum share in the market because medications are often prescribed after a thorough diagnosis which is often conducted at these institutions. Retail pharmacies segment is expected to hold the second-largest share owing to its efficient facilities in cases of re-filling prescriptions. The online pharmacies segment will experience a growth significant rate owing to its increasing popularity because of the ease and convenience.

• Geography: Under this segment, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The cardiovascular drugs market size in North America was valued at USD 21.89 Billion in 2018 and is projected to remain dominant during the forecast period. The increasing prevalence of cardiovascular and heart diseases along with new product launches across the region is driving the market in North America. Moreover, increasing R&D activities and growing awareness will further contribute growth to the market. Asia Pacific is predicted to experience high growth due to increasing disposable incomes across the region. Furthermore, the increasing prevalence of cardiovascular diseases in the region will accelerate the growth of the market in the region.

List of the Leading Players in the Global Cardiovascular Drugs Market are:

• Bristol-Myers Squibb Company


• Pfizer Inc.


• Bayer AG


• Janssen Pharmaceuticals, Inc.


• AstraZeneca


• Sanofi


• Novartis AG


• Merck & Co., Inc.


• Gilead Sciences, Inc.


• F. Hoffmann-La Roche Ltd


• Others

Launch of New Drugs by Key Players will Aid Expansion

October 2019: The Food and Drug Administration (FDA) announced the approval of the additional disease indication of the prevention of venous thromboembolism (VTE) in hospitalized acutely ill medical patients at risk for thromboembolic complications but not at high risk of bleeding for Janssen Pharmaceuticals, Inc.’s product offering of rivaroxaban (Xarelto)

February 2019: Novartis AG and Blackstone’s Life Sciences announced the launch of Anthos Therapeutics for the development of cardiovascular drugs.

The Global Cardiovascular Drugs Market is Segmented into: